Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Japan Tobacco Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Japan Tobacco Inc. - Product Pipeline Review - 2014', provides an overview of the Japan Tobacco Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Japan Tobacco Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Japan Tobacco Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Japan Tobacco Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Japan Tobacco Inc.'s pipeline products Reasons to buy - Evaluate Japan Tobacco Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Japan Tobacco Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Japan Tobacco Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Japan Tobacco Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Japan Tobacco Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Japan Tobacco Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Japan Tobacco Inc. Snapshot 6 Japan Tobacco Inc. Overview 6 Key Information 6 Key Facts 6 Japan Tobacco Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Japan Tobacco Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Japan Tobacco Inc. - Pipeline Products Glance 17 Japan Tobacco Inc. - Late Stage Pipeline Products 17 Phase III Products/Combination Treatment Modalities 17 Japan Tobacco Inc. - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Japan Tobacco Inc. - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Japan Tobacco Inc. - Drug Profiles 21 (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 TO-206 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 JTT-851 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 JTZ-951 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 JTE-051 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 JTE-052 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 JTK-351 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 JTT-251 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 JTT-252 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 OR-1050 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Vaccine for Cedar Pollen Allergy 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Japan Tobacco Inc. - Pipeline Analysis 33 Japan Tobacco Inc. - Pipeline Products by Target 33 Japan Tobacco Inc. - Pipeline Products by Route of Administration 34 Japan Tobacco Inc. - Pipeline Products by Molecule Type 35 Japan Tobacco Inc. - Pipeline Products by Mechanism of Action 36 Japan Tobacco Inc. - Recent Pipeline Updates 37 Japan Tobacco Inc. - Dormant Projects 40 Japan Tobacco Inc. - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 JTK-652 41 JTT-553 41 JTV-803 41 dalcetrapib 42 elvitegravir 42 encaleret 42 granotapide 42 JTE-607 42 JTK-003 42 JTK-656 42 JTK-853 42 JTS-653 43 JTT-302 43 JTT-551 43 JTT-552 43 JTT-651 43 JTT-654 43 MEDI-570 43 Japan Tobacco Inc. - Company Statement 44 Japan Tobacco Inc. - Locations And Subsidiaries 46 Head Office 46 Other Locations & Subsidiaries 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Japan Tobacco Inc., Key Information 6 Japan Tobacco Inc., Key Facts 6 Japan Tobacco Inc. - Pipeline by Indication, 2014 9 Japan Tobacco Inc. - Pipeline by Stage of Development, 2014 10 Japan Tobacco Inc. - Monotherapy Products in Pipeline, 2014 11 Japan Tobacco Inc. - Combination Treatment Modalities in Pipeline, 2014 12 Japan Tobacco Inc. - Partnered Products in Pipeline, 2014 13 Japan Tobacco Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14 Japan Tobacco Inc. - Out-Licensed Products in Pipeline, 2014 15 Japan Tobacco Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16 Japan Tobacco Inc. - Phase III, 2014 17 Japan Tobacco Inc. - Phase II, 2014 18 Japan Tobacco Inc. - Phase I, 2014 19 Japan Tobacco Inc. - Preclinical, 2014 20 Japan Tobacco Inc. - Pipeline by Target, 2014 33 Japan Tobacco Inc. - Pipeline by Route of Administration, 2014 34 Japan Tobacco Inc. - Pipeline by Molecule Type, 2014 35 Japan Tobacco Inc. - Pipeline Products by Mechanism of Action, 2014 36 Japan Tobacco Inc. - Recent Pipeline Updates, 2014 37 Japan Tobacco Inc. - Dormant Developmental Projects,2014 40 Japan Tobacco Inc. - Discontinued Pipeline Products, 2014 41 Japan Tobacco Inc., Subsidiaries 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.